Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 3/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | USP1 | O94782 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17242514 | 1.00 | FEN1 (0.50) | FEN1CA9CA12PGRCYP17A1 | |
| SCHEMBL17242787 | 1.00 | FEN1 (0.50) | FEN1CA9CA12PGRCYP17A1 | |
| SCHEMBL17242746 | 0.90 | FEN1 (0.52) | FEN1PGRCYP17A1MAPK1OPRM1 | |
| SCHEMBL17242807 | 0.90 | CA9 (0.55) | CA9CA12CMA1MAPK1OPRM1 | |
| SCHEMBL17242800 | 0.90 | CA9 (0.55) | CA9CA12CMA1MAPK1OPRM1 | |
| SCHEMBL17241505 | 0.84 | PGR (0.49) | CA9CA12PGRMAPK1OPRM1 | |
| SCHEMBL17241504 | 0.84 | PGR (0.49) | CA9CA12PGRMAPK1OPRM1 | |
| SCHEMBL17242519 | 0.84 | PGR (0.49) | CA9CA12PGRMAPK1OPRM1 | |
| SCHEMBL17241978 | 0.82 | PARP1 (0.44) | CA9CA12PGRCMA1MAPK1 | |
| SCHEMBL17242763 | 0.82 | PARP1 (0.44) | CA9CA12PGRCMA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137387-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | ORION CORPORATION (FI) | 2017-05-18 | — | — | US | disclosed |
| EP-3140301-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | Orion Corporation (FI) | 2017-03-15 | — | — | EP | disclosed |
| WO-2015169999-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | ORION CORPORATION (FI) | 2015-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137387-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | GABRB1, GABRB3, GABRB2 | FEN1 4680/4885CA9 3799/4885CA12 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.